Accordingly, cyclin D1 is a candidate protein that can be targeted in different ways: by inhibition of chromosome band 11q13 and/or CCND1; by direct cyclin D1 inhibition; by CDK inhibition, acting upstream on melanoma-related pathways that involve cyclin D1; or by combining agents that act against cyclin D1 with other antitumor drugs. The gene discussed is CCND1; the disease is melanoma.